Lupin gets nod to launch Metronidazole antibiotic in the US

Lupin said it received final approval to market a generic version of G.D. Searle LLC Flagyl antibiotic tablets in the US.

Flagyl tablets had US sales of USD 44.1 million

Lupin’s Metronidazole Tablets USP, 250 mg and 500 mg are the AB rated generic equivalent of the drug.

It is indicated in the treatment of wide variety of infections which are caused by particular types of bacteria and other infectious organisms.

Lupin will launch its drug in two doses, 250 mg and 500 mg.

The Indian pharma giant focuses on Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 7th largest generics pharmaceutical company by market capitalization and the and sixth largest by revenues.

The Company is the 4th largest pharmaceutical player in the US by prescriptions and the second largest Indian pharmaceutical company by global revenues.